U.S. Markets open in 2 hrs 32 mins

MiMedx Group, Inc. (MDXG)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
14.84-0.15 (-1.00%)
At close: 4:00PM EDT
People also watch
OSIRNEOHALOMACKTGTX

MiMedx Group, Inc.

1775 West Oak Commons Court, NE
Marietta, GA 30062
United States
770-651-9100
http://www.mimedx.com

SectorHealthcare
IndustryMedical Appliances & Equipment
Full Time Employees690

Key Executives

NameTitlePayExercisedAge
Mr. Parker H. PetitChairman and Chief Exec. Officer605.7kN/A78
Mr. William Charles TaylorPres, Chief Operating Officer and Director506.26kN/A49
Mr. Michael J. SenkenChief Financial Officer, Principal Accounting Officer and VP365.04kN/A59
Ms. Alexandra O. HadenGen. Counsel and Sec.331.67kN/A42
Dr. Thomas J. Koob Ph.D.Chief Scientific OfficerN/AN/A68
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MiMedx Group, Inc. develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human placental tissue, skin, and bone. The company collects the donated human placental tissue and converts into a sterile product through its proprietary PURION process. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Corporate Governance

MiMedx Group, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 2; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.